Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,172,691 | 1,873,397 | 1,192,428 | 554,845 | 1,726,115 |
| Depreciation Amortization | 574,260 | 434,789 | 287,672 | 142,467 | 595,813 |
| Accounts receivable | -129,887 | -413,936 | -182,786 | -189,822 | 35,599 |
| Accounts payable and accrued liabilities | -268,845 | -349,771 | -296,012 | -258,661 | 288,980 |
| Other Working Capital | -1,247,698 | -1,211,361 | -840,533 | -626,300 | -461,670 |
| Other Operating Activity | 1,503,496 | 1,099,266 | 618,329 | 620,535 | -476,894 |
| Operating Cash Flow | $2,604,017 | $1,432,384 | $779,098 | $243,064 | $1,707,943 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -263,600 | -221,269 | -107,354 | -72,931 | -170,252 |
| Net Acquisitions | -354,020 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -6,217 | -4,280 | -3,559 | -66 | -32,605 |
| Sale Of Investment | 139,000 | 134,890 | 134,398 | 64,960 | 88,625 |
| Purchase Sale Intangibles | -702,222 | -457,273 | -62,525 | -48,577 | -518,764 |
| Other Investing Activity | -735,679 | -471,000 | -78,950 | -59,614 | -536,199 |
| Investing Cash Flow | $-1,220,515 | $-561,659 | $-55,465 | $-67,650 | $-650,432 |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -997,054 | -759,902 | -530,442 | -171,683 | -529,884 |
| Dividend Paid | -577,805 | -570,843 | -287,738 | -287,738 | -565,529 |
| Other Financing Activity | -31,008 | -6,519 | -3,838 | -1,607 | -6,762 |
| Financing Cash Flow | $-1,605,867 | $-1,337,264 | $-822,017 | $-461,029 | $-1,102,174 |
| Exchange Rate Effect | -79,755 | 7,536 | 30,373 | 81,483 | 90,691 |
| Beginning Cash Position | 3,290,369 | 3,250,726 | 3,250,726 | 3,250,726 | 3,561,503 |
| End Cash Position | 2,988,249 | 2,791,723 | 3,182,715 | 3,046,604 | 3,607,513 |
| Net Cash Flow | $-302,128 | $-459,003 | $-68,011 | $-204,123 | $46,019 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,604,017 | 1,432,384 | 779,098 | 243,064 | 1,707,943 |
| Capital Expenditure | -278,150 | -234,766 | -119,941 | -75,735 | -219,847 |
| Free Cash Flow | 2,325,867 | 1,197,618 | 659,157 | 167,329 | 1,488,096 |